Blood and lymphatic system disorders – page 90

Study of Ravulizumab for Children with Thrombotic Microangiopathy After Stem Cell Transplant

Study of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory Lymphomas After CAR T-cell Therapy

Study of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory Lymphomas After CAR T-cell Therapy

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Study on the Safety and Effectiveness of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study on the Safety and Effectiveness of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma

Study of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma

Study on [68Ga]Ga-PentixaFor and [18F]FDG PET/CT Imaging for Staging Marginal Zone Lymphoma in Patients with Confirmed Diagnosis

Study on [68Ga]Ga-PentixaFor and [18F]FDG PET/CT Imaging for Staging Marginal Zone Lymphoma in Patients with Confirmed Diagnosis

Study Comparing Obinutuzumab and Venetoclax with Obinutuzumab and Chlorambucil for Untreated Chronic Lymphocytic Leukemia Patients with Other Health Conditions

Study Comparing Obinutuzumab and Venetoclax with Obinutuzumab and Chlorambucil for Untreated Chronic Lymphocytic Leukemia Patients with Other Health Conditions

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Study of NMS-03592088 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Study of NMS-03592088 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Study on Brentuximab Vedotin and Drug Combination for Patients with Peripheral T-cell Lymphoma with Less Than 10% CD30 Expression

Study on Brentuximab Vedotin and Drug Combination for Patients with Peripheral T-cell Lymphoma with Less Than 10% CD30 Expression

Study on the Safety and Effects of BAY 2599023 (Peboctocogene Camaparvovec) for Adults with Severe Hemophilia A

Study on the Safety and Effects of BAY 2599023 (Peboctocogene Camaparvovec) for Adults with Severe Hemophilia A

Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma